Wedbush Analysts Boost Earnings Estimates for KNSA

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) – Equities research analysts at Wedbush upped their Q1 2025 earnings estimates for shares of Kiniksa Pharmaceuticals in a research note issued to investors on Tuesday, February 25th. Wedbush analyst D. Nierengarten now forecasts that the company will earn $0.31 per share for the quarter, up from their previous forecast of $0.10. Wedbush has a “Outperform” rating and a $34.00 price objective on the stock. The consensus estimate for Kiniksa Pharmaceuticals’ current full-year earnings is ($0.55) per share. Wedbush also issued estimates for Kiniksa Pharmaceuticals’ Q2 2025 earnings at $0.38 EPS, Q3 2025 earnings at $0.47 EPS, Q4 2025 earnings at $0.52 EPS, FY2025 earnings at $1.69 EPS, FY2026 earnings at $2.55 EPS and FY2027 earnings at $3.24 EPS.

Separately, JPMorgan Chase & Co. raised their price objective on shares of Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the company an “overweight” rating in a research report on Tuesday, November 5th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $36.60.

Kiniksa Pharmaceuticals Stock Performance

Kiniksa Pharmaceuticals stock opened at $19.63 on Thursday. The firm’s fifty day moving average price is $19.66 and its 200-day moving average price is $22.55. The stock has a market cap of $1.42 billion, a P/E ratio of -140.20 and a beta of 0.32. Kiniksa Pharmaceuticals has a fifty-two week low of $16.56 and a fifty-two week high of $28.15.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last posted its earnings results on Tuesday, February 25th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.06). The firm had revenue of $122.50 million during the quarter, compared to analysts’ expectations of $123.42 million. Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The business’s revenue for the quarter was up 46.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.35 earnings per share.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in KNSA. Quarry LP bought a new position in shares of Kiniksa Pharmaceuticals during the 3rd quarter valued at $50,000. Lazard Asset Management LLC bought a new stake in Kiniksa Pharmaceuticals in the 4th quarter worth $61,000. KLP Kapitalforvaltning AS bought a new stake in Kiniksa Pharmaceuticals in the 4th quarter worth $158,000. Bellevue Group AG bought a new stake in Kiniksa Pharmaceuticals in the 4th quarter worth $160,000. Finally, Tower Research Capital LLC TRC grew its holdings in Kiniksa Pharmaceuticals by 117.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 8,483 shares of the company’s stock worth $168,000 after acquiring an additional 4,575 shares during the last quarter. Institutional investors own 53.95% of the company’s stock.

Insider Activity at Kiniksa Pharmaceuticals

In related news, CFO Mark Ragosa sold 8,969 shares of the stock in a transaction on Tuesday, December 3rd. The shares were sold at an average price of $21.45, for a total transaction of $192,385.05. Following the transaction, the chief financial officer now owns 22,958 shares of the company’s stock, valued at approximately $492,449.10. This trade represents a 28.09 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Eben Tessari sold 14,000 shares of the stock in a transaction on Monday, January 13th. The shares were sold at an average price of $18.24, for a total transaction of $255,360.00. Following the transaction, the chief operating officer now directly owns 88,975 shares in the company, valued at approximately $1,622,904. This represents a 13.60 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 38,092 shares of company stock valued at $745,589. Insiders own 54.57% of the company’s stock.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.